A Study of Language Interpretation Solutions for People With Breast Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The study will be conducted in 2 overlapping phases. In Phase 1, there will be a 3-arm randomized controlled trial of Remote Simultaneous Medical Interpreting/RSMI (Arm 1), versus Remote Consecutive Medical Interpreting/RCMI (Arm 2) and versus Remote Consecutive Video Medical Interpreting/RCVI (Arm 3) in breast cancer outpatient clinical encounters with Spanish- and Mandarin-speaking patients with Limited English Proficiency/LEP (Stages II and III disease) and English- speaking providers (who do not speak Spanish/Mandarin). In Phase 2, there will be a sequential mixed-methods explanatory, multi-stakeholder process evaluation to gather implementation potential data.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age >=18 years (per EMR)
Preferred language for healthcare is Spanish or Mandarin (per self-report)
Limited English Proficient; cannot speak English "very well" (per self-report)
Diagnosis of breast cancer or gastrointestinal (per EMR)
Disqualifiers
Has significant psychiatric disturbance (i.e., acute psychiatric symptoms) sufficient to preclude completion of the assessments, interviews, or informed consent (per EMR, patient's care team, or study team)
Presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patients, care team, or study team)
None
None
Trial design
Design model
Parallel
Treatments tested in this trial
Remote Simultaneous Medical Interpreting/RSMI
Other interventionRemote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter, which holds tremendous promise for closely approximating a same language encounter, decreasing interpreting errors, and improving outcomes.
Remote Consecutive Medical Interpreting/RCMI
Other interventionRemote Consecutive Medical Interpreting (RCMI; "audio consecutive"), is the most commonly utilized remote interpreting
Remote Consecutive Video Medical Interpreting/RCVI
Other interventionRemote Simultaneous Medical Interpreting (RSMI), "UN-style" simultaneous interpreting applied to the medical encounter
Treatment groups
700 Participants
are divided into 4 treatment groupsGroup A: Phase I: Remote Simultaneous Medical Interpreting/RSMI (Arm 1)Experimental treatment 1 intervention
Group B: Phase I: Remote Consecutive Medical Interpreting/RCMI (Arm 2)Experimental treatment 1 intervention
Group C: Phase I: Remote Consecutive Video Medical Interpreting/RCVI (Arm 3)Experimental treatment 1 intervention
Group D: Phase II: CFIR mixed-methods explanatory, multi- stakeholder process evaluationExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Number of interpretation errors
Via translation and transcription of audio recordings, errors will be determined in the interpretation of medical facts made in each of the RCT arms during Study Visit 1 (post- diagnosis)
Time frame
up to 30 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov